We read with great interest the article recently published in
Brain by Johannesen and colleagues,
1 which revealed the clear genotype-phenotype correlations between the age at seizure onset, type of epilepsy and gain-of-function (GOF) or loss-of-function (LOF) effects of
SCN8A variants. The authors collected the largest cohort of individuals with
SCN8A-related epilepsy from a multi-country study and found that generalized epilepsy with absence seizures is the main epilepsy phenotype of LOF variant carriers and the extent of the electrophysiological dysfunction of the GOF variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Their pharmacological data indicated that sodium channel blockers (SCBs) present a treatment option in the
SCN8A-related focal epilepsy with onset in the first year of life.
1